With the factor XI inhibitor, clinicians may have more flexibility when managing anticoagulation in this common scenario.

Based on these numbers, the researchers estimated that 5-year cumulative risks of recurrent events were 17.4% for ischemic ...

Community cardiology specialist Dr Peter Savill discusses five key challenges for GPs in the management of atrial ...

There is an apparent underuse of warfarin in elderly patients with AF, as there is inconsistency in opinion among clinicians about who should receive anticoagulation. The risks of warfarin are ...

I've been diagnosed with atrial fibrillation. I've read that it puts me at greater risk of stroke. Can you tell me more about ...

– For people who have heart failure with a normal heart rhythm, there seems to be little to no advantage of warfarin (an anticoagulant: a medicine which prevents blood clotting by blocking proteins) ...

As we observed World Heart Rhythm Week (June 2–8, 2025), the theme “One Heart, Many Rhythms” underscored the importance of ...

Atrial fibrillation (AF) is the most common cardiac arrhythmia, and its incidence increases with age. Current data suggest that anticoagulation with warfarin or dabigatran is far superior to ...

The Ischemic Stroke Epidemiology Forecast Report 2025-2034 offers extensive analysis on prevalence trends and demographic influences of ischemic stroke globally. Covering eight key markets, it details ...

Patients with AF and ACHD that receive NOAC, compared with VKA, for stroke prevention have lower risk of all-cause mortality.

Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded the novel anticoagulant ...

Background Anticoagulation therapy reduces stroke risk in patients with atrial fibrillation (AF), but it is often underused in older populations due to concerns about bleeding. This study aimed to ...